Cisplatin neuropathy in brain tumor chemotherapy

A. Sghirlanzoni, A. Silvani, V. Scaioli, D. Pareyson, R. Marchesan, A. Boiardi

Research output: Contribution to journalArticlepeer-review


38 patients with glial brain tumors received 135 mg/m2 cisplatin intravenously every month for 5 courses. Signs and symptoms of peripheral neuropathy were evaluated clinically and electrophysiologically. This approach differs from methods previously reported in that it offers two major advantages: primary brain tumors do not cause paraneoplastic neuropathy; no neurotoxic drugs other than cisplatin were employed. Our study confirmed in this highly specific clinical model the existence of cisplatin peripheral neuropathy: we observed definite clinical signs or symptoms of neuropathy in 80% of patients receiving a cumulative cisplatin dosage of 675 mg/m2; there was a progressive dose-related decrease in SAP amplitudes, expression of a sensory axonopathy or neuronopathy.

Original languageEnglish
Pages (from-to)311-315
Number of pages5
JournalItalian Journal of Neurological Sciences
Issue number4
Publication statusPublished - May 1992


  • chemotherapy
  • Cisplatin
  • peripheral nerve diseases

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Cisplatin neuropathy in brain tumor chemotherapy'. Together they form a unique fingerprint.

Cite this